Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Oct;19(5):388-95.
doi: 10.1016/j.breast.2010.03.025. Epub 2010 Apr 10.

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

Kelly-Anne Phillips  1 , Karin Ribi, Zhuoxin Sun, Alisa Stephens, Alastair Thompson, Vernon Harvey, Beat Thürlimann, Fatima Cardoso, Olivia Pagani, Alan S Coates, Aron Goldhirsch, Karen N Price, Richard D Gelber, Jürg Bernhard
Affiliations
Randomized Controlled Trial

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

Kelly-Anne Phillips et al. Breast. 2010 Oct.

Abstract

Cognitive function in postmenopausal women receiving letrozole or tamoxifen as adjuvant endocrine treatment was compared during the fifth year of treatment in a substudy of the BIG 1-98 trial. In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed by 3-years letrozole, or (D) 2-years letrozole followed by 3-years tamoxifen. The primary comparison was the difference in composite score for patients taking letrozole (B+C; N=65) vs. tamoxifen (A+D; N=55). The patients taking letrozole had better overall cognitive function than those taking tamoxifen (difference in mean composite z-scores=0.28, P=0.04, 95% CI: 0.02, 0.54, Cohen's D=0.40 indicating small to moderate effect). In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Treatment Schema for the BIG 1-98 trial Cognitive Function Substudy. Patients were assessed at the fifth year, toward the end of endocrine treatment and again at year 6, one year later. A total of 120 patients are included in the substudy analysis. [Color figure may be printed in grayscale.]
Fig 2
Fig 2
Estimated difference in means of the z-scores; negative values indicate cognitive function below age-adjusted norms. The p-values and 95% CIs of the treatment effects on tasks are based on the two-way ANOVA controlling for the effect of language. The percentages indicate the proportion of patients with “impaired” scores in the respective tasks (score >1.96 SD below the age-adjusted norm).
Fig 3
Fig 3
Estimated difference in means of the z-scores comparing letrozole vs. tamoxifen for the primary analysis population and monotherapy arms only (A), and comparing the monotherapy vs. sequential arms for the patients in the tamoxifen and letrozole groups (B). The p-values and 95% CIs of the treatment effects on tasks are based on the two-way ANOVA controlling for the effect of language.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. J Natl Cancer Inst. 2003;95:190–197. - PubMed
    1. Vardy J, Wefel JS, Ahles T, et al. Cancer and cancer-therapy related cognitive dysfunction: An international perspective from the Venice cognitive workshop. Ann Oncol. 2008;19:623–629. - PubMed
    1. Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev. 2003;24:133–151. - PubMed
    1. Ciocca DR, Roig LM. Estrogen receptors in human non-target tissues: biological and clinical implications. Endocr Rev. 1995;16:35–37. - PubMed
    1. Sumner BE, Grant KE, Rosie R, et al. Effects of tamoxifen on serotonin transporter and 5-hydroxytryptamine receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement. Brain Res Mol Brain Res. 1999;73:119–128. - PubMed

Publication types

MeSH terms